CAM Capital

CAM Capital is a principal investment firm based in New York, specializing in direct investments across both private and public markets. Founded in 2012, the firm employs a diversified and opportunistic investment strategy aimed at achieving long-term compounded growth within its portfolio. CAM Capital focuses on special situations and operates across various sectors, primarily targeting opportunities in the Americas and Western Europe. The firm engages in trading activities and fundamentally driven investments, and it often collaborates with external partners to enhance its investment approach.

Scott Morenstein

Managing Director

22 past transactions

Palvella Therapeutics

Post in 2024
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Kyverna Therapeutics

Series B in 2023
Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, Kyverna employs advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells, which are responsible for the inflammation associated with these diseases. By addressing the root causes of autoimmune conditions, Kyverna aims to provide more effective and lasting solutions for patients suffering from these challenging health issues.

Kriya Therapeutics

Series C in 2022
Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

AvengeBio

Series A in 2022
AvengeBio is a biotechnology company based in Cambridge, Massachusetts, focused on developing cell-generated immunotherapies aimed at eradicating solid tumors. Founded in 2019, the company is advancing a drug delivery platform designed to enable the precision delivery of cytokines and other potent immunomodulatory molecules. This innovative approach allows for controlled release over time, fostering robust local and systemic anti-tumor immune responses while minimizing the toxicities typically associated with conventional immunotherapies. Through its research and development efforts, AvengeBio seeks to address the challenges posed by intractable solid tumors and improve treatment outcomes for cancer patients.

Kriya Therapeutics

Series B in 2021
Kriya Therapeutics, Inc. is a gene therapy company focused on creating innovative treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, Kriya Therapeutics has developed a fully integrated platform that consolidates the essential infrastructure and technology for the engineering, manufacturing, characterization, and clinical development of gene therapies. The company utilizes a vector design platform that enhances its ability to design new constructs, modify sequences, and analyze data, ultimately enabling physicians to reduce immunogenicity and enhance tissue specificity in their therapeutic approaches.

AltruBio

Series A in 2021
AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.

Antios Therapeutics

Series B in 2021
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Primmune Therapeutics

Series A in 2020
Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Rezolute

Post in 2020
Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

ESSA Pharma

Post in 2020
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.

Cardiff Oncology

Post in 2020
Cardiff Oncology is a clinical-stage biotechnology company based in San Diego, California, focused on developing innovative cancer therapies. Its lead drug candidate, onvansertib, is a selective Polo-like Kinase 1 inhibitor currently undergoing Phase Ib/II clinical trials for acute myeloid leukemia and metastatic colorectal cancer, as well as a Phase II trial for metastatic castration-resistant prostate cancer in combination with Zytiga. The company also explores other therapeutics, including belinostat and quizartinib, targeting various cancers such as leukemias, lymphomas, and solid tumors. Cardiff Oncology utilizes proprietary technology to analyze circulating tumor DNA, aiding in the identification of actionable markers for cancer treatment response. The company has established a research collaboration with Nektar Therapeutics to further enhance its cancer treatment offerings. Founded in 1999 and previously known as Trovagene, Cardiff Oncology is dedicated to addressing significant unmet medical needs in oncology.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Primmune Therapeutics

Seed Round in 2020
Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Antios Therapeutics

Series A in 2018
Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

MEI Pharma

Post in 2018
MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

GTx

Post in 2017
GTx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specializes in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders, targeting conditions such as breast cancer and Duchenne muscular dystrophy. One of its notable product candidates is enobosarm GTx-024, which is undergoing Phase II clinical trials for patients with specific types of breast cancer and postmenopausal women suffering from stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aims to advance medical solutions by leveraging new scientific approaches. In 2019, GTx was acquired by Oncternal Therapeutics in a reverse merger.

Molecular Templates

Post in 2017
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Kala Pharmaceuticals

Series C in 2016
Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Velicept Therapeutics

Series B in 2015
Velicept Therapeutics, Inc. is a clinical development company based in Malvern, Pennsylvania, established in 2015. The company is dedicated to advancing innovative therapies for conditions such as overactive bladder (OAB) and irritable bowel syndrome (IBS), focusing on unmet medical needs. Its lead program features Solabegron, a novel and selective compound that relaxes bladder smooth muscle by stimulating beta 3-adrenoceptors. This therapeutic approach aims to enhance the quality of life for patients suffering from OAB and IBS. Velicept Therapeutics is committed to developing best-in-class treatment options to transform patient care in these areas.

Cidara Therapeutics

Series B in 2015
Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Agile Therapeutics

Post in 2015
Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

Infinity SDC

Venture Round in 2013
Infinity SDC is a prominent UK data centre operator renowned for its strategically located facilities near London. The company specializes in the design, construction, and maintenance of efficient data centres that help clients reduce energy costs and carbon emissions. Infinity offers a comprehensive range of premium services, including shared and bespoke data halls tailored to client needs. Its customer base includes leading investment banks, cloud vendors, systems integrators, and telecommunications companies. Known for its resilience, flexibility, and security, Infinity aims to exceed client expectations both commercially and technically.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.